SCHEDULE: BAT Increases Strategic Stake in Organigram

British American Tobacco has expanded its investment in Organigram Global Inc. following the acquisition of Sanity Group GmbH and a concurrent private placement.

Summary

• Completed the acquisition of Sanity Group GmbH on April 15, 2026, to expand international market presence.
• BT DE Investments Inc., a subsidiary of British American Tobacco (BAT), received 943,900 Common Shares and 12,638,228 Preferred Shares as upfront consideration for its stake in Sanity.
• BAT participated in a private placement, purchasing 1,152,800 Common Shares and 12,874,274 Preferred Shares at C$3.00 per share.
• BAT exercised existing top-up rights for 9,897,356 Preferred Shares at approximately C$2.335854 per share.
• BAT now beneficially owns 29.9% of outstanding Common Shares and 100% of the newly issued Class A Preferred Shares.
• The Preferred Shares feature a conversion rate that increases by 7.5% annually, providing a yield-like benefit to the holder.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive validation of Organigram's strategy, as a major global partner has increased its financial and governance commitment, though the dilutive terms are significant for minority holders.

Positives

• Secured strong financial backing and continued commitment from a global leader, British American Tobacco.
• Successful completion of the Sanity Group GmbH acquisition provides a foothold in the European market.
• BAT elected to receive equity instead of cash for its interest in Sanity, signaling long-term confidence in the company's valuation.
• The private placement provided necessary capital to fund the cash component of the acquisition and transaction expenses.

Negatives

• Significant dilution for existing minority shareholders due to the issuance of over 2 million common shares and over 35 million preferred shares.
• The 7.5% annual increase in the Preferred Share conversion rate creates persistent dilutive pressure on common equity.
• Concentration of control is high, with BAT holding rights to nominate up to 30% of the Board of Directors.

Risks

• Achievement of specific financial performance metrics for Sanity Group is required for the full earnout of 6,625,559 additional shares.
• Potential for further dilution if Preferred Shares are converted or if the 30% common share ownership threshold is adjusted.
• Exposure to international regulatory shifts in the cannabis industry following the Sanity Group acquisition.

Future Outlook

BAT intends to review its investment continuously and may increase or decrease its stake based on market conditions. The potential issuance of 6,625,559 additional Common Shares as earnout consideration depends on Sanity Group's financial performance over the next 12 months.

Management Comments

• The Purchaser intends to review its investment in the Issuer on a continuing basis.
• The investment was made in furtherance of a strategic investment in the Issuer.
• The Purchaser is permitted to engage with the Board regarding the Issuer's business and prospects.

Industry Context

StockSavvy.ai notes that this move reinforces the trend of major tobacco companies seeking diversification into the cannabis and wellness sectors through strategic equity stakes in established operators, mirroring similar moves by Altria and Philip Morris.

Comparison to Industry Standards

• BAT's 29.9% stake in Organigram is comparable to Altria's significant investment in Cronos Group, though with more complex preferred share structures.
• The 7.5% annual yield/conversion increase on preferred shares is a highly favorable term for the investor compared to standard equity placements in the cannabis sector.
• The C$3.00 floor for earnout shares provides a protective valuation benchmark similar to structured deals seen in high-growth biotech sectors.

Corporate Governance

Related Party Transactions

• The acquisition involved the Issuer purchasing shares of Sanity Group from the Purchaser (a BAT subsidiary).
• The Purchaser received OGI shares in lieu of cash for its interest in Sanity Group.

Stakeholder Impact

• Common shareholders face immediate dilution from the issuance of new common and preferred shares.
• The company gains a strengthened balance sheet and a new international asset in Sanity Group.
• Management gains a more flexible debt financing framework under the new investor rights agreement.

Next Steps

• Monitoring of Sanity Group's financial performance for the 12-month earnout period.
• Potential conversion of Preferred Shares into Common Shares as the 30% threshold allows.
• Appointment or replacement of nominee directors by BAT to fill up to 30% of the Board seats.

Key Dates

Recommendation

While the backing of a global giant like BAT is a strong long-term signal, the immediate dilution and the complex structure of the preferred shares suggest a cautious approach until the integration of Sanity Group shows clear revenue and EBITDA contributions.

Keywords

Cannabis, Strategic Investment, M&A, British American Tobacco, Organigram, Sanity Group, Private Placement, Equity Issuance